Aditxt Inc. (ADTX) Completes Reverse Split, Shares Surge Over 20%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: NASDAQ.COM
- Stock Price Surge: Aditxt Inc. saw its stock price rise over 20% to $1.44 in premarket trading on Wednesday, indicating strong market confidence in its immune modulation technologies and future growth prospects.
- Reverse Stock Split: The company executed a 1-for-113 reverse stock split on January 11, 2026, aimed at maintaining compliance with Nasdaq's minimum bid price requirements, thereby enhancing its market appeal and compliance status.
- Special Shareholder Meeting: Aditxt has scheduled a virtual special shareholder meeting for January 30, 2026, where shareholders will vote on significant capital and governance proposals, including the authorization of convertible preferred stock, which could profoundly impact the company's future financing capabilities.
- Employee Stock Purchase Plan: The meeting will propose the adoption of a 2025 Employee Stock Purchase Plan reserving 200,000 shares, designed to incentivize employees and strengthen the internal shareholder structure, thereby enhancing employee engagement and productivity.
Analyst Views on ADTX
About ADTX
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
